Fintel reports that on November 19, 2024, Evercore ISI Group upgraded their outlook for BioNTech SE - Depositary Receipt () ...
Echoing this, BioNTech stock's Schaeffer's put/call open interest ratio (SOIR) of 1.14 sits higher than 98% of annual ...
In a report released today, Harry Gillis from Berenberg Bank upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price target of $130.00. The company’s shares closed yesterday at $101.87.
Zacks.com on MSN5d
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock UpBioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...
BioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to strengthen its oncology pipeline. With the acquisition, BNTX will gain full ...
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated ...
Barchart on MSN7h
Stocks Recover from Early Losses on Strength in Nvidia and WalmartThe Nasdaq 100 recovered from early losses and turned higher on strength in Super Micro Computer and Nvidia. Stock indexes also found support in strong earnings results from Walmart, which rose more ...
Shares of BioNTech stock opened at $99.72 on Thursday. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback